Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Sitravatinib in Combination with Tislelizumab in Advanced Biliary Tract Cancer After Prior Systemic Therapy
KCT0005512Phase 2Not yet recruiting
- Sponsor
- BeiGene
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitravatinib, tislelizumab in biliary cancer, sponsored by BeiGene. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
sitravatinibtislelizumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0005512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005512.